You are here

PET Reagents for Normal and Tumor Tissue Hypoxia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 1R41CA093124-01
Amount: $99,515.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
115 MILL ST BELMONT, MA 02478-9106
BELMONT, MA 02478
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES RALEIGH
 (919) 966-7710
 RALEIGH@RADONC.UNC.EDU
Business Contact
 LEE, TINA
Phone: (617) 855-2188
Email: NPI@MCLEAN.HARVARD.EDU
Research Institution
 UNIVERSITY OF NORTH CAROLINA
 
UNIVERSITY OF NORTH CAROLINA
CHAPEL HILL, NC 25879
United States

 Nonprofit college or university
Abstract

DESCRIPTION (provided by applicant): Disruption of O2 gradients in normal
tissues creates major medical problems including cardiovascular disease,
stroke, diabetes, liver and kidney damage and organ transplant failure. Steep
O2 gradients in tumors protect tumor cells from cytotoxic therapies and create
more aggressive tumors. Measurements of O2 gradients are clearly needed. This
study proposes F-18 positron emission tomography (PET) reagents based on
Hypoxyprobe(TM) markers for non-invasive assays of normal and malignant tissue
hypoxia. Hypoxyprobe(TM) PET markers will have: high water solubility; chemical
stability; universal tissue distribution; short plasma half-life; low toxicity;
and, high tissue adduct stability. Hypoxyprobe(TM) kits are already marketed
for studies of tissue hypoxia by flow cytometry, ELISA and immunohistology. PET
reagents would be an exciting addition. The synthesis of fluorinated
Hypoxyprobe(TM) analogues will be optimized and promising analogues tested in
single cell suspensions and in multicellular spheroid systems for their ability
to discriminate cells at different levels of hypoxia. Binding of the
fluorinated analogues will be quantitated immunochemically by means of
monoclonal antibodies raised against the Hypoxyprobe(TM) analogues. Analogues
whose synthesis is rapid and clean with respect to fluoride incorporation and
whose ability to discriminate hypoxic cells is optimal will be tested in animal
PET facilities in Phase II STTR studies.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government